BofA rates Supernus Pharmaceuticals a buy, citing strong CNS drug growth and revenue boosts from acquisitions. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback